-
First-in-class cholesterol-lowering treatment NILEMDO® ▼ (bempedoic acid) tablet and its combination with ezetimibe NUSTENDI® ▼ (bempedoic acid and ezetimibe) tablet approved in SwitzerlandDaiichi Sankyo2021-02-02 11:33:17First-in-class cholesterol-lowering treatment NILEMDO® ▼ (bempedoic acid) tablet and its combination with
-
TROPION-Lung05 Phase 2 Trial of Datopotamab Deruxtecan Initiated in Patients with Advanced or Metastatic NSCLC with Actionable Genomic AlterationsDaiichi Sankyo2020-12-14 15:35:37TROPION-Lung05 Phase 2 Trial of Datopotamab Deruxtecan Initiated in Patients with Advanced or Metastatic NSCLC
-
TROPION-Lung01 Head-to-Head Phase 3 Trial Initiated to Evaluate Datopotamab Deruxtecan Versus Docetaxel in Previously Treated Patients with Advanced or Metastatic NSCLC Without Actionable Genomic AlterationsDaiichi Sankyo2020-12-14 15:36:13TROPION-Lung01 Head-to-Head Phase 3 Trial Initiated to Evaluate Datopotamab Deruxtecan Versus Docetaxel in
-
Trastuzumab Deruxtecan Recommended for Approval in the EU by CHMP for HER2 Positive Metastatic Breast CancerDaiichi Sankyo2020-12-14 14:49:29Trastuzumab Deruxtecan Recommended for Approval in the EU by CHMP for HER2 Positive Metastatic Breast Cancer
-
Results from First Combination Trial of ENHERTU® and Immune Checkpoint Inhibitor in Patients with HER2 Expressing Metastatic Breast Cancer Presented at the 2020 San Antonio Breast Cancer SymposiumDaiichi Sankyo2023-11-10 06:53:58Results from First Combination Trial of ENHERTU® and Immune Checkpoint Inhibitor in Patients with HER2
-
ENHERTU® Continues to Demonstrate Durable Responses with New Data from DESTINY-Breast01 in HER2 Positive Metastatic Breast CancerDaiichi Sankyo2023-11-10 06:54:59ENHERTU® Continues to Demonstrate Durable Responses with New Data from DESTINY-Breast01 in HER2 Positive
-
Daiichi Sankyo to Present New Data for HER2 and HER3 Directed DXd ADCs at SABCSDaiichi Sankyo2023-11-10 06:54:38Daiichi Sankyo to Present New Data for HER2 and HER3 Directed DXd ADCs at SABCS
-
Pooled analyses show NILEMDO®▼ significantly lowers cholesterol in different subgroups in Phase 3 data presented at AHA 2020Daiichi Sankyo2020-11-16 10:51:13Pooled analyses show NILEMDO®▼ significantly lowers cholesterol in different subgroups in Phase 3 data
-
Daiichi Sankyo Creates New Business Unit to Unify Major Oncology Markets into One Streamlined Organization Dedicated to Patients with CancerDaiichi Sankyo2020-11-11 20:09:14Daiichi Sankyo Creates New Business Unit to Unify Major Oncology Markets into One Streamlined Organization
-
DESTINY-Breast05 Head-to-Head Phase 3 Trial of ENHERTU® Versus T-DM1 Initiated in Patients with HER2 Positive Early Breast Cancer at High Risk After Neo-adjuvant TherapyDaiichi Sankyo2023-11-09 21:02:38DESTINY-Breast05 Head-to-Head Phase 3 Trial of ENHERTU® Versus T-DM1 Initiated in Patients with HER2 Positive
